Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 1
1971 1
1975 1
1976 1
1990 1
1993 1
1996 1
1998 1
1999 1
2000 3
2001 2
2002 2
2003 6
2004 6
2005 3
2006 3
2007 5
2008 6
2009 3
2010 1
2011 3
2012 2
2013 3
2014 7
2015 7
2016 7
2017 4
2018 8
2019 9
2020 13
2021 10
2022 22
2023 12
2024 8
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Results by year

Filters applied: . Clear all
Page 1
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis.
Lidar M, Rimar D, David P, Jacoby E, Shapira-Frommer R, Itzhaki O, Slobodin G, Stern MD, Eshed I, Sanalla T, Marcus R, Shimoni A, Yerushalmi R, Shem Tov N, Danylesko I, Avigdor A. Lidar M, et al. Among authors: avigdor a. Ann Rheum Dis. 2025 Feb;84(2):370-372. doi: 10.1136/ard-2024-226437. Epub 2025 Jan 2. Ann Rheum Dis. 2025. PMID: 39919909 No abstract available.
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma.
Raj SS, Fei T, Fried S, Ip A, Fein JA, Leslie LA, Alarcon Tomas A, Leithner D, Peled JU, Corona M, Dahi PB, Danylesko I, Epstein-Peterson Z, Funnell T, Giralt SA, Jacoby E, Kedmi M, Landego I, Lin RJ, Parascondola A, Pascual L, Orozco N, Park JH, Palomba ML, Salles G, Saldia A, Schöder H, Sdayoor I, Shah GL, Scordo M, Shem-Tov N, Shimoni A, Slingerland J, Yerushalmi R, Nagler A, Greenbaum BD, Vickers AJ, Suh HC, Avigdor A, Perales MA, van den Brink MRM, Shouval R. Raj SS, et al. Among authors: avigdor a. Nat Med. 2025 Apr;31(4):1183-1194. doi: 10.1038/s41591-025-03532-x. Epub 2025 Apr 1. Nat Med. 2025. PMID: 40169864 Free PMC article.
T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy.
Rejeski K, Sanz J, Fei T, Nair MS, Hashmi H, Avigdor A, Beyar-Katz O, Bücklein VL, Curran KJ, Einarsdottir S, Esensten JH, Glaubach N, Golan-Accav N, Gomez-Llobell M, Halamis I, Itzhaki O, Locke FL, Mailankody S, Marcus R, Maus MV, Palomba ML, Park JH, Pasquini M, Raj S, Rajeeve S, Salles G, Scordo M, Shah GL, Shimoni A, Subklewe M, Tix T, Usmani SZ, Valid O, Valtis YK, Zuckerman T, Shah NN, Perales MA, Shouval R. Rejeski K, et al. Among authors: avigdor a. Blood. 2025 Aug 14;146(7):834-846. doi: 10.1182/blood.2025028833. Blood. 2025. PMID: 40258181 Free article.
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma.
Deschênes-Simard X, Bromberg M, Devlin SM, Gonen M, Beyar-Katz O, Ip A, Marcus R, Avigdor A, Ballweg A, Rabinovich E, Alhomoud M, Rivas Delgado A, Corona De Lapuerta M, Luna De Abia A, Palomba ML, Shah GL, Lin R, Boardman AP, Falchi L, Lue J, Salles G, Perales MA, Shouval R, Dahi PB, Scordo M. Deschênes-Simard X, et al. Among authors: avigdor a. Blood Adv. 2025 Nov 11;9(21):5571-5584. doi: 10.1182/bloodadvances.2025016778. Blood Adv. 2025. PMID: 40815804 Free PMC article.
Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience.
Cassanello G, Luttwak E, Brown S, Devlin SM, Imber B, Ip A, Leslie LA, Accav NG, Avigdor A, Marcus R, Beyar-Katz O, Corona M, Luna De Abia A, Calabrese De Feo J, Rivas Delgado A, Lue JK, Grommes C, Shah GL, Park J, Perales MA, Salles G, Shouval R, Scordo M, Palomba ML. Cassanello G, et al. Among authors: avigdor a. Br J Haematol. 2025 Aug;207(2):525-534. doi: 10.1111/bjh.20234. Epub 2025 Jul 1. Br J Haematol. 2025. PMID: 40589238
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study.
Trněný M, Avigdor A, McKinney MS, Paneesha S, Wahlin BE, Hrom JS, Cunningham D, Morley N, Canales M, Bastos-Oreiro M, Belada D, Devizzi L, Zheng F, DeMarini DJ, Jiang W, Jiang P, Lynch RC. Trněný M, et al. Among authors: avigdor a. EClinicalMedicine. 2023 Aug 18;63:102130. doi: 10.1016/j.eclinm.2023.102130. eCollection 2023 Sep. EClinicalMedicine. 2023. PMID: 37662520 Free PMC article.
Distinct cellular and molecular patterns in pre-treatment peripheral blood are associated with CAR-T cell outcomes in diffuse large B-cell lymphoma.
Gurevich-Shapiro A, Zwicky P, Winter E, Zada M, Shapira N, Barboy O, Chalan P, Sharet-Eshed R, Kedmi M, Ingelfinger F, Phan TS, David E, Shouval R, Luan D, Raj SS, Shapiro M, Itzhaki O, Golan-Accav N, Avigdor A, Avivi I, Weiner A, Ram R, Amit I. Gurevich-Shapiro A, et al. Among authors: avigdor a. Cancer Res. 2025 Oct 10. doi: 10.1158/0008-5472.CAN-25-3596. Online ahead of print. Cancer Res. 2025. PMID: 41071708
152 results